NANOAOD: a new compact event data format in CMS

The CMS Collaboration has recently commissioned a new compact data format, named NANOAOD, reducing the per-event storage space requirement to about 1-2 kB. This represents a factor 20 reduction in storage space compared to the MINIAOD data format used previously for physics analysis at CMS. We envisage that the information stored in the NANOAOD data format is sufficient to support the majority of CMS physics analyses. NANOAOD also facilitates the dissemination of analysis methods and the automation of standard workflows for deriving conditions and object calibrations. The latest developments of this project will be presented.

The Effect of MSCs Derived from the Human Umbilical Cord Transduced by Fibroblast Growth Factor-20 on Parkinson’s Disease

Cell therapy is a potential therapeutic approach for Parkinson’s disease (PD). Mesenchymal stem cells derived from the human umbilical cord (hUC-MSCs) give priority to PD patients because of multiple advantages. The appropriate gene transduction of hUC-MSC before transplantation is a promising procedure for cell therapy. Fibroblast growth factor-20 (FGF-20) has been shown to protect dopaminergic neurons against a range of toxic insults in vitro. In this study, the hUC-MSCs were gene transduced with FGF-20, and then we transplanted them into the PD mice model. The results showed that MSC-FGF-20 treatment obviously improved the behavior of PD, accompanied by the increase of tyrosine carboxylase- (TH-) positive cell and dopamine (DA). Furtherly, immunohistochemistry disclosed that MSC-FGF-20 obviously promoted the degradation of nuclear factor-κB (NF-κB), a transcription factor that controls genes encoding proinflammatory cytokines, highly expressed in the nigrostriatal dopaminergic regions in PD patients. Therefore, MSC-FGF-20 has a potential for improving PD, closely related to the degradation of NF-κB.